TGA AI Medical Scribe Regulation: When Clinical Software Becomes a Medical Device

Australia's Therapeutic Goods Administration (TGA) has clarified that many AI-powered digital scribes are considered medical devices, not simple administrative tools. Following a review published on October 16, 2023, the TGA found that 8 of 12 reviewed products were likely unapproved medical devices. This episode breaks down the TGA's reasoning, focusing on how a software's intended purpose—such as summarizing or analyzing clinical information—triggers regulatory oversight. We discuss the immediate compliance obligations for manufacturers and provide practical steps for developers of Software as a Medical Device (SaMD) to navigate this evolving regulatory landscape. Key Questions: - What did the TGA's review of AI digital scribes reveal on October 16, 2023? - Why are some AI scribes now considered medical devices in Australia? - What is the key difference between an administrative tool and a Software as a Medical Device (SaMD)? - What immediate actions must manufacturers of unapproved AI scribes take? - How does a product's intended purpose affect its regulatory classification? - What are the steps for including an SaMD product in the Australian Register of Therapeutic Goods (ARTG)? - What risks do developers face if they continue to supply non-compliant software? - How can manufacturers conduct a gap analysis against TGA requirements? Sources: - https://www.racgp.org.au/newsgp/professional/ai-medical-scribes-face-stricter-tga-oversight - https://www.tga.gov.au/news/news/digital-scribe-review-outcomes How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you access global markets faster. For SaMD developers targeting Australia, we offer expert regulatory strategy, technical dossier preparation for TGA submissions, and local representation services to ensure your product meets all compliance requirements. Our combination of local expertise and advanced AI tools streamlines the path to market, from initial classification to post-market surveillance. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI-powered regulatory tools and global device database at https://pureglobal.ai.